MARKET

GPCR

GPCR

Structure Therapeutics Inc ADR
NASDAQ
68.40
+0.06
+0.09%
Opening 14:16 12/29 EST
OPEN
68.00
PREV CLOSE
68.34
HIGH
68.92
LOW
66.58
VOLUME
266.90K
TURNOVER
--
52 WEEK HIGH
94.90
52 WEEK LOW
13.22
MARKET CAP
4.73B
P/E (TTM)
-18.7490
1D
5D
1M
3M
1Y
5Y
1D
My Market Outlook For 2026: Focus On Pharma For Consistent Returns, Potential Skyrocketing Shares
Seeking Alpha · 3h ago
Weekly Report: what happened at GPCR last week (1222-1226)?
Weekly Report · 10h ago
NVO's First Oral Obesity Pill Approval: What Does it Mean for Lilly?
NASDAQ · 5d ago
Novo Nordisk Wins FDA Nod for Oral Wegovy in Obesity, Stock Up
NASDAQ · 6d ago
Regencell Bioscience is the top performing pharma stock YTD
Seeking Alpha · 6d ago
Weekly Report: what happened at GPCR last week (1215-1219)?
Weekly Report · 12/22 09:09
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Benzinga · 12/21 14:30
Structure Therapeutics Inc. - Depositary Receipt (GPCR) Price Target Increased by 21.89% to 94.31
NASDAQ · 12/21 10:48
More
About GPCR
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.

Webull offers Structure Therapeutics Inc (ADR) stock information, including NASDAQ: GPCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GPCR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GPCR stock methods without spending real money on the virtual paper trading platform.